What if curing cancer could cost 99% less in China?
A decade ago, treating cancer with personalised mRNA vaccines seemed like a US$1 million gamble per patient, a therapy reserved for the ultra-rich. But Chinese biotech start-ups are aiming to change that – by designing cancer therapy for a fraction of the cost and also taking on Western pharmaceutical giants in the process. Beijing-based Likang…
